Cytology applications of p63 and TTF-1 immunostaining in differential diagnosis of lung cancers

Diagnostic Cytopathology

Volumn 33, Issue 4, 2005, Pages 223-227

  Wu, Maoxin ^a   Szporn, Arnold H ^a   Zhang, David ^a   Wasserman, Patricia ^b   Gan, Li ^a   Miller, Lorraine ^a   Burstein, David E ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b LONG ISLAND JEWISH MEDICAL CENTER   (United States)

Author keywords

Cytology; Lung cancer; p63; TTF 1

Indexed keywords

BIOTIN; CHROMOGENIC SUBSTRATE; DIAMINOBENZIDINE; HEMATOXYLIN; MONOCLONAL ANTIBODY; PROTEIN P63; STREPTAVIDIN; SYNAPTOPHYSIN; THYROID TRANSCRIPTION FACTOR 1;

ADRENAL BIOPSY; ARTICLE; ASPIRATION BIOPSY; AUTOSTAINER; CANCER CYTODIAGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC KIT; DIFFERENTIAL DIAGNOSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; INSTRUMENT; LIVER BIOPSY; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG LAVAGE; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LYMPH NODE BIOPSY; METASTASIS; PELVIS TUMOR; PLEURA EFFUSION; POORLY DIFFERENTIATED LUNG SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL; TUMOR DIFFERENTIATION;

ADENOCARCINOMA; BIOPSY, FINE-NEEDLE; CARCINOMA, SMALL CELL; CARCINOMA, SQUAMOUS CELL; DIAGNOSIS, DIFFERENTIAL; DNA-BINDING PROTEINS; GENES, TUMOR SUPPRESSOR; HUMANS; LUNG NEOPLASMS; LYMPH NODES; NUCLEAR PROTEINS; PHOSPHOPROTEINS; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 25444434622     PISSN: 87551039     EISSN: None     Source Type: Journal    
DOI: 10.1002/dc.20337     Document Type: Article

References (35)

1. Wang BY, Gil J, Kaufman D, Li G, Kohtz DS, Burstein DE. p63 in pulmonary epithelium, pulmonary squamous neoplasms and other pulmonary tumors. Hum Pathol 2002;33:921-926.
2. Pelosi G, Pasini F, Olsen Stenholm C, et al. p63 immunoreactivity in lung cancer: yet another player in the development of squamous cell carcinomas? J Pathol 2002;198:100-109.
3. Di Como CJ, Urist MJ, Babayan I, et al. p63 expression profiles in human normal and tumor tissues. Clin Cancer Res 2002;8:494-501.
4. Reis-Filho JS, Simpson PT, Martins A, et al. Distribution of p63, cytokeratins 5/6 and cytokeratin 14 in 51 normal and 400 neoplastic human tissue samples using TARP-4 multi-tumor tissue microarray. Virchows Arch 2003;443:122-132.
5. Massion PP, Taflan PM, Jamshedur Rahman SM, et al. Significance of p63 amplification and overexpression in lung cancer development and prognosis. Cancer Res 2003;63:7113-7121.
6. Sheikh HA, Fuhrer K, Cieply K, Yousem S. p63 expression in assessment of bronchioloalveolar proliferations of the lung. Mod Pathol 2004;17:1134-1140.
7. Wang TY, Chen BF, Yang YC, et al. Histologic and immunophenotypic classification of cervical carcinomas by expression of the p53 homologue p63: a study of 250 cases. Hum Pathol 2001;32:479-486.
8. Choi HR, Batsakis JG, Zhan F, Sturgis E, Luna MA, El-Naggar AK. Differential expression of p53 gene family members p63 and p73 in head and neck squamous tumorigenesis. Hum Pathol 2002;33:158-164.
9. Reis-Filho JS, Torio B, Albergaria A, Schmitt FC. p63 expression in normal skin and usual cutaneous carcinomas. J Cutan Pathol 2002;29:517-523.
10. Glickman JN, Yang A, Shahsafaei A, McKeon F, Odze RD. Expression of p53-related protein p63 in the gastrointestinal tract and in esophageal metaplastic and neoplastic disorders. Hum Pathol 2001;32:1157-1165.
11. Black CC, Unger PD, Gans WH, et al. Expression of p63 protein in subtypes of transitional cell and renal cell carcinoma (Abstract). Mod Pathol 2001;14:102A.
12. Park BJ, Lee SJ, Kim JI, et al. Frequent alteration of p63 expression in human primary bladder carcinomas. Cancer Res 2000;60:3370-3374.
13. Unger P, Ewart M, Wang BY, Li G, Kohtz DS, Burstein DE. Expression of p63 in papillary thyroid carcinoma and in Hashimoto's thyroiditis: a pathobiologic link? Hum Pathol 2003;34:764-769.
14. O'Connell JT, Mutter GL, Cviko A, et al. Identification of a basal/reserve cell immunophenotype in benign and neoplastic endometrium: a study with the p53 homologue p63. Gynecol Oncol 2001;80:30-36.
15. Johansson L. Histopathologic classification of lung cancer: relevance of cytokeratin and TTF-1 immunophenotyping. Ann Diagn Pathol 2004;8:259-267.
16. Liu J, Farhood A. Immunostaining for thyroid transcription factor-1 on fine-needle aspiration specimens of lung tumors: a comparison of direct smears and cell block preparations. Cancer 2004;102:109-114.
17. Chang YL, Lee YC, Liao WY, Wu CT. The utility and limitation of thyroid transcription factor-1 protein in primary and metastatic pulmonary neoplasms. Lung Cancer 2004;44:149-157.
18. Yang DT, Holden JA, Florell SR. CD117, CK20, TTF-1, and DNA topoisomerase 11-alpha antigen expression in small cell tumors. J Cutan Pathol 2004;31:254-261.
19. Myong NH. Thyroid transcription factor-1 (TTF-1) expression in human lung carcinomas: its prognostic implication and relationship with expressions of p53 and Ki-67 proteins. J Korean Med Sci 2003;18:494-500.
20. Yatabe Y, Mitsudomi T, Takahashi T. TTF-1 expression in pulmonary adenocarcinomas. Am J Surg Pathol 2002;26:767-773.
21. Sturm N, Rossi G, Lantuejoul S, et al. Expression of thyroid transcription factor-1 in the spectrum of neuroendocrine cell lung proliferations with special interest in carcinoids. Hum Pathol 2002;33:175-182.
22. Ordonez NG. Value of thyroid transcription factor-1 immunostaining in distinguishing small cell lung carcinomas from other small cell carcinomas. Am J Surg Pathol 2000;24:1217-1223.
23. Kaufmann O, Dietel M. Expression of thyroid transcription factor-1 in pulmonary and extrapulmonary small cell carcinomas and other neuroendocrine carcinomas of various primary sites. Histopathology 2000;36:415-420.
24. Agoff SN, Lamps LW, Philip AT, et al. Thyroid transcription factor-1 is expressed in extrapulmonary small cell carcinomas but not in other extrapulmonary neuroendocrine tumors. Mod Pathol 2000;13:238-242.
25. Chieng DC, Cangiarella JF, Zakowski MF, Goswami S, Cohen JM, Yee HT. Use of thyroid transcription factor 1, PE-10, and cytokeratins 7 and 20 in discriminating between primary lung carcinomas and metastatic lesions in fine-needle aspiration biopsy specimens. Cancer 2001;93:330-336.
26. Folpe AL, Gown AM, Lamps LW, et al. Thyroid transcription factor-1: immunohistochemical evaluation in pulmonary neuroendocrine tumors. Mod Pathol 1999;12:5-8.
27. Harlamert HA, Mira J, Bejarano PA, et al. Thyroid transcription factor-1 and cytokeratins 7 and 20 in pulmonary and breast carcinoma. Acta Cytol 1998;42:1382-1328.
28. Di Loreto C, Di Lauro V, Puglisi F, Damante G, Fabbro D, Beltrami CA. Immunocytochemical expression of tissue specific transcription factor-1 in lung carcinoma. J Clin Pathol 1997;50:30-32.
29. Fabbro D, Di Loreto C, Stamerra O, Beltrami CA, Lonigro R, Damante G. TTF-1 gene expression in human lung tumours. Eur J Cancer 1996;32A:512-517.
30. Wu M, Wang B, Gil J, et al. p63 and TTF-1 Immunostaining: a useful marker panel for distinguishing small cell carcinoma of lung from poorly differentiated squamous cell carcinoma of lung. Am J Clin Pathol 2003;119:696-702.
31. Shtilbans V, Szporn AH, Wu M, Burstein DE. p63 immunostaining in destained bronchoscopic cytologic specimens. Diagn Cytopathol 2005;32:198-203.
32. Au NH, Gown AM, Cheang M, et al. P63 expression in lung carcinoma: a tissue microarray study of 408 cases. Appl Immunohistochem Mol Morphol 2004;12:240-247.
33. Zhang H, Liu J, Cagle PT, Allen TC, Laga AC, Zander DS. Distinction of pulmonary small cell carcinoma from poorly differentiated squamous cell carcinoma: an immunohistochemical approach. Mod Pathol 2005;18:111-118.
34. DeMay RM. The art and science of cytopathology. Chicago, IL: ASCP; 1996. p 961-962,970.
35. DeMay RM. The art and science of cytopathology. Chicago, IL: ASCP; 1996. p 974-975.